Recurrent High-grade Glioma
Conditions
Interventions
patients group :ultra-low dose Bevacizumab plus Temozolomide
Sponsors
Hebei Yanda Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. High grade glioma was diagnosed by post-operation pathological method, and shows a relapse; 2. Before included, the patient needs imageological examinations, and the diameter of contrast enhancing area is bigger than 1cm, PET or MRS results show positive features; 3. The age of patient should be between 18 years old and 70 years old; 4. The condition of the patient permits the treatment of ultra-low dose Bevacizumab plus Temozolomide; 5. The patient is informed consent,and willing to join in this research.
Exclusion criteria
Exclusion criteria: 1. The diagnosis is not recurrent high-grade glioma; 2. The diagnosis of high-grade glioma was not established by pathological method; 3. The results of imageological examinations do not meet the standard of including; 4. the age of the patient does not meet the requirement of this research; 5. the condition of the patient does not permit the treatement of ultra-low dose Bevacizumab plus Temozolomide; 6. there are other conditions that the clinicans believe that the treatment of ultra-low dose Bevacizumab plus Temozolomide is not appropriate for the patient; 7. the patient is not willing to join in this research.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall survival of recurrent GBM;Overall survival of recurrent WHO-III glioma;Progression free survival of recurrent GBM;Progression free survival of recurrent WHO-III glioma;6-month life quality;12-month life quality; | — |
Primary
| Measure | Time frame |
|---|---|
| 6-month survival rate of recurrent GBM;12-month survival rate of recurrent WHO-III glioma; | — |
Countries
China
Contacts
Public ContactWang Jisheng,Ji Nan
Outcome results
None listed